Hailan Liu, PA-C, PhD

This physician is not currently rated. Why?

Why is this doctor not rated?

Close

To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles. Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive evaluation and ratings from patients.

More about patient ratings

Advanced Practice Clinician

​Physician Assistant

Treatment Focus

Survivorship planning for patients with melanoma.

Treatment Philosophy

Where you start your cancer care matters!
I am honored to be part of the surgical oncology team providing care for patients with skin cancer (including melanoma, merkel cell carcinoma, advance squamous cell carcinoma), sarcomas, and gastrointestinal cancers. I treasure my relationship with my patients and thrive to provide the very best care for patients who undergo surgery and throughout the rest of their cancer journey. I follow early stage melanoma patients as well as melanoma survivors in the survivor clinic.

Clinical Locations

Educational Background

  • MS,Physician Assistant Studies, Indiana University, Indianapolis, IN, 2015
  • PhD, Pharmacology, Indiana University School of Medicine, Indianapolis, IN, 2008
  • BS, Biochemistry, Nanjing University, China, 1998

Certifications

  • National Commission on Certification of Physician Assistants- Certified, 2015-Present
  • Physician Assistant - Certified, Pennsylvania State License
  • Physician Assistant Certified

Memberships

  • Member, American Society of Clinical Oncology
  • Society of Surgical Oncology (SSO)
  • Association of Physician Assistants in Oncology (APAO)

Selected Publications

Moslim, M., Li, H., Lefton, M., Ruth, K., Nagarathinam, R.,Cooper, H., Reddy, S. Survival and Recurrence in Pancreatobiliary Versus Intestinal Histology of Ampullary Carcinoma. Journal of clinical oncology and research, August 2001. DOI: 10.31487/j.COR.2021.08.09

Renzetti M , Solimon I , Loo K , Lamb E , Wu H , Luo B,  Liu H, Olszanski A, Movva S, Lango M , Reddy S,  Farma JM. Molecular Profiling in Patients with Nodular versus Superficial Spreading Melanoma. Annual Academic Surgical Congress Abstract ID ACS20180209. Jacksonville, FL, Feb 2018

Renzetti M, Soliman I, Wu H, Luo B, Liu H, Olszansi A, Movva S, Lango M, Reddy S. Zih F. Farma JM. Evaluation of Molecular Profile in High Risk Class 2 MelanomaDx Melanoma Patients. Annual Academic Surgical Congress-Quick Shot Presentation. Las Vegas, NV; February 2017

Fan, Q., Gu, D., Liu, H. et al and Xie, J. Defective TGF-β in bone marrow-derived cell prevents Hedgehog-induced skin tumors. Cancer Res. 74(2): 471-83, 2014

Gu D., Liu H., Su G., et al and Xie J. Combining Hedgehog signaling inhibition with focal irradiation on reduction of pancreatic cancer metastasis. Mol Cancer Ther. 12(6): 1038-48, 2013

Liu H., Wu, X. Dong, Z., et al and Zhang, J. T. Fatty acid synthase causes drug resistance by inhibiting TNF-α and ceramide production. J Lipid Res, 54 (3): 776-85, 2013 

Liu, H., Liu, J., Wu, X and Zhang, J.T. Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. Int J Biochem Mol Bio. 1(1): 69–89, 2010

Yang, Y., Liu, H., et al and Zhang, J.T. Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers. Int J Biochem Mol Biol. 2(1): 89–98, 2011

Liu, H., Liu, Y. and Zhang, J.T. A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction. Mol Cancer Ther. 7(2):263-70,2008

Liu, Y.; Liu, H.; Han, B.; Zhang, J.T. Identification of 14-3-3- as a contributor to drug resistance in human breast cancer cells using functional proteomics analysis.  Cancer Res.66(6):3248-3255,2006